All In Biotech

Drug Trial Radar · NCT04938427

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

270

Actual

Start

Nov 8, 2021

Primary completion

Jan 25, 2024

Study completion Jan 25, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aims of the study are: * to learn if soticlestat, when given as add-on therapy, reduces the number of major motor drop seizures in children, teenagers, and adults with Lennox-Gastaut Syndrome. * to assess the safety profile of soticlestat when given in combination with other therapies. Participants will receive their standard antiseizure therapy, plus either tablets of soticlestat or placebo. A placebo looks just like soticlestat but will not have any medicine in it. Participants will take soticlestat or placebo for 16 weeks, followed by a gradual dose reduction for 1 week. Then, participants will be followed up for 2 weeks.

Conditions

  • Lennox Gastaut Syndrome (LGS)

Interventions

  • PlaceboDrug

    Soticlestat placebo-matching mini-tablets or tablets.

  • SoticlestatDrug

    Soticlestat mini-tablets or tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days During the Full Treatment PeriodTime frame: Baseline; Full Treatment Period: Weeks 1 to 16
  2. Percent Change From Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days During the Maintenance PeriodTime frame: Baseline; Maintenance Period: Weeks 5 to 16

Locations

98 sites in 18 countries. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Center For Neurosciences

    Tucson, Arizona

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • University of California Benioff Children's Hospital

    San Francisco, California

  • Children's Hospital Colorado.

    Denver, Colorado

  • Pediatric Neurology PA

    Winter Park, Florida

  • Clinical Integrative Research Center of Atlanta

    Atlanta, Georgia

  • University of Iowa Hospitals & Clinics - (CRS)

    Iowa City, Iowa

  • Midatlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • Minnesota Epilepsy Group PA

    Roseville, Minnesota

  • Institute of Neurology and Neurosurgery at Saint Barnabas, LLC

    Livingston, New Jersey

  • Premier Healthcare Inc.

    New York, New York

  • NYU Comprehensive Epilepsy Center

    New York, New York

  • Northwell Health Physician Partners - Neurology at Lenox Hill

    New York, New York

  • Oregon Health and Science University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • St. Christopher's Hospital for Children

    Philadelphia, Pennsylvania

  • WellSpan Oncology Research

    York, Pennsylvania

  • Medical University of South Carolina Children Hospital - PIN

    Charleston, South Carolina

  • Cook Children's Medical Center - Jane and John Justin Neurosciences Center

    Fort Worth, Texas

  • University of Utah - Primary Children's Hospital - PPDS

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • MultiCare Institute for Research & Innovation (Tacoma)

    Tacoma, Washington

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia

  • Queensland Childrens Hospital

    South Brisbane, Queensland, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Hopital Universitaire des Enfants Reine Fabiola

    Brussels, Belgium

  • UZ Antwerpen PIN

    Edegem, Antwerpen, Belgium

  • Centre Neurologique William Lennox

    Ottignies-Louvain-la-Neuve, Brabant Wallon, Belgium

  • Alberta Childrens Hospital

    Calgary, Alberta, Canada

  • Child and Family Research Institute

    Vancouver, British Columbia, Canada

  • Hospital For Sick Children

    Toronto, Ontario, Canada

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Children's Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

  • Children's Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Guangzhou Women And Children's Medical Center

    Guangzhou, Guangdong, China

  • Shenzhen Children's Hospital

    Shenzhen, Guangdong, China

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.